Should I buy or sell TherapeuticsMD stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks .

How have TXMD shares performed in 2024?

TherapeuticsMD's stock was trading at $2.25 at the beginning of 2024. Since then, TXMD stock has decreased by 13.3% and is now trading at $1.95. View the best growth stocks for 2024 here .

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TXMD earnings forecast .

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter.

When did TherapeuticsMD's stock split?

Shares of TherapeuticsMD reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK) , Verastem (VSTM) , Teva Pharmaceutical Industries (TEVA) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Sorrento Therapeutics (SRNE) , Gilead Sciences (GILD) , Cleveland-Cliffs (CLF) , Novavax (NVAX) and Micron Technology (MU) .

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free TXMD Stock Alerts

$2.01

+0.06 (+3.08%)

(As of 10:59 AM ET)

Compare

Today's Range: $1.86
▼
$2.02
50-Day Range: $1.95
▼
$2.69
52-Week Range: $1.86
▼
$4.73

Volume: 33,610 shs
Average Volume: 21,468 shs
Market Capitalization: $23.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get TherapeuticsMD alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About TherapeuticsMD Stock (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TXMD Stock News Headlines

April 13, 2024 | americanbankingnews.com

StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

April 7, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 29, 2024 | businesswire.com

TherapeuticsMD Announces Full Year 2023 Financial Results

March 12, 2024 | msn.com

25 Countries With Highest Abortion Rates

March 10, 2024 | sg.finance.yahoo.com

TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance

December 29, 2023 | morningstar.com

TherapeuticsMD Inc TXMD

November 15, 2023 | nasdaq.com

Daily Markets: Today Brings Producer Prices, Retail Sales Data

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

November 14, 2023 | marketwatch.com

TherapeuticsMD to Consider Strategic Alternatives

November 14, 2023 | msn.com

TherapeuticsMD exploring strategic alternatives for company

November 14, 2023 | finance.yahoo.com

TherapeuticsMD Announces Third Quarter 2023 Financial Results

October 4, 2023 | bizjournals.com

Boca Raton-based prescription service announces layoffs, says a third of workforce could be cut

September 20, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Wednesday, underperforms market

August 15, 2023 | marketwatch.com

TherapeuticsMD Inc. stock outperforms market despite losses on the day

August 14, 2023 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2023 Financial Results

August 9, 2023 | finance.yahoo.com

Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors

July 5, 2023 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors

July 4, 2023 | thestreet.com

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

May 23, 2023 | seekingalpha.com

TherapeuticsMD: From Fallen And Forgotten To Cash Cow

May 15, 2023 | finance.yahoo.com

TherapeuticsMD Announces First Quarter 2023 Financial Results

May 10, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Tuesday, underperforms market

May 10, 2023 | marketwatch.com

TherapeuticsMD Inc. stock rises Wednesday, still underperforms market

May 3, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Monday, underperforms market

April 30, 2023 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors

April 23, 2023 | marketwatch.com

TherapeuticsMD Inc. stock outperforms market on strong trading day

April 14, 2023 | msn.com

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

See More Headlines

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2023
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TXMD
Previous Symbol: NYSEMKT:TXMD
CUSIP: N/A
CIK: 25743
Web: www.therapeuticsmd.com
Phone: (561) 961-1900
Fax: 561-431-3389
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,280,000.00
Net Margins: N/A
Pretax Margin: -594.62%
Return on Equity: -25.54%
Return on Assets: -14.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.72
Quick Ratio: 1.72

Sales & Book Value

Annual Sales: $1.30 million
Price / Sales: 17.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.77 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 11,530,000
Free Float: 11,394,000
Market Cap: $23.00 million
Optionable: Optionable
Beta: 1.03

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Governor Thomas G. Thompson (Age 82)
Executive Chairman
Comp: $150k
Mr. Marlan D. Walker J.D. (Age 48)
Chief Executive Officer
Comp: $1.13M
Mr. Robert G. Finizio (Age 53)
Co-Founder
Comp: $7.51k
Mr. Michael C. Donegan (Age 56)
Interim CFO & Chief Accounting Officer
Comp: $712.59k
Ms. Daniella Silva (Age 38)
Chief Compliance Officer
Mr. Benjamin Foulk (Age 54)
Vice President of Human Resources
Mr. Bharat Warrier (Age 46)
Chief Manufacturing Officer
Mr. Douglas Steelman
Vice President of Market Access
Ms. Dedra Lyden
Vice President of Strategic Partnerships & Initiatives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings or view top-rated stocks.
How have TXMD shares performed in 2024?: TherapeuticsMD's stock was trading at $2.25 at the beginning of 2024. Since then, TXMD stock has decreased by 13.3% and is now trading at $1.95.
View the best growth stocks for 2024 here.
When is TherapeuticsMD's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our TXMD earnings forecast.
How were TherapeuticsMD's earnings last quarter?: TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter.

When did TherapeuticsMD's stock split?: Shares of TherapeuticsMD reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of TherapeuticsMD own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).
How do I buy shares of TherapeuticsMD?: Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXMD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial